Popular Trials
Evidence Impact on Biologics Confidence for Psoriasis
This trial will study whether patients are more confident in the potential success of biologic medications in treating their psoriasis after being presented with clinical trial evidence, anecdotal evidence, or both.
Monoclonal Antibodies
Ustekinumab for Psoriasis
This trial is looking to see if researchers can predict which psoriasis drugs will work for individual patients by looking at markers or gene patterns. Participants will try two different drugs for 8 weeks at a time and have their skin monitored for improvement.
Popular Filters
Trials for Psoriasis Patients
Phosphodiesterase 4 (PDE4) Inhibitor
Long-Term Apremilast Use for Psoriasis
This trial provides the option to continue apremilast treatment for up to 4 years for those who complete an initial 52-week trial. There will be an 8-week observational follow-up phase.
TENS for Psoriasis Injection Pain
This trial is testing whether TENS therapy can reduce pain during and after the injection of biological medications. 10-20 subjects will be recruited and will receive the injection in one thigh with and one without the use of TENS therapy.
Phase 3 Trials
Phosphodiesterase 4 (PDE4) Inhibitor
Long-Term Apremilast Use for Psoriasis
This trial provides the option to continue apremilast treatment for up to 4 years for those who complete an initial 52-week trial. There will be an 8-week observational follow-up phase.
Monoclonal Antibodies
Subcutaneous Guselkumab for Psoriasis
This trial is testing a medication called guselkumab to see if it is safe and effective for children and teenagers with chronic plaque psoriasis. The medication aims to reduce inflammation and slow down the rapid growth of skin cells. Guselkumab is the first IL-23 specific inhibitor to be approved for the treatment of plaque psoriasis and has shown excellent safety and efficacy in previous studies.
Trials With No Placebo
Phosphodiesterase 4 (PDE4) Inhibitor
Long-Term Apremilast Use for Psoriasis
This trial provides the option to continue apremilast treatment for up to 4 years for those who complete an initial 52-week trial. There will be an 8-week observational follow-up phase.
TENS for Psoriasis Injection Pain
This trial is testing whether TENS therapy can reduce pain during and after the injection of biological medications. 10-20 subjects will be recruited and will receive the injection in one thigh with and one without the use of TENS therapy.
View More Related Trials
Frequently Asked Questions
Introduction to plaque psoriasis
What are the top hospitals conducting plaque psoriasis research?
When it comes to pioneering clinical trials in the treatment of plaque psoriasis, several hospitals are making notable strides. In Houston, the Center for Clinical Studies is leading the way with three ongoing trials focused on this dermatological condition. With a total of 32 conducted studies dedicated to plaque psoriasis since their first recorded trial in 2004, this center has solidified its position as a prominent player in the field. Meanwhile, Brigham and Women's Hospital in Boston is also actively involved in advancing treatments for plaque psoriasis through their three currently active trials and their early involvement starting from 2003 with five completed studies.
On the East Coast, The Psoriasis Treatment Center of Central New jersey located at East Windsor offers hope to patients living with plaque psoriasis through its dedication to research. This institution has initiated three active clinical trials focused on finding effective therapies for this condition since recording its inaugural trial in 2015. Alongside these determined efforts lies Wake Forest University Health Sciences based in Winston-Salem where they too have enkindled required enthusiasm by conducting eighteen experiments until now from commencing investigation about such cases back during year- 2006.
Although Skin Sciences, PLLC may seem relatively new compared to other institutions listed here, located in Louisville they contribute significantly towards medical advancements by actively participating via two ongoing clinical tests while already having four previously held investigations under their belt; all being related exclusively towards understanding Plaque Psoriasis beginning only after recording particular type of experiment attached back during uncertain times i.e.,2017
These esteemed hospitals signify not only remarkable progress but also unwavering commitment when it comes to improving outcomes for those grappling with plaque psoriasis—a chronic skin condition that affects millions worldwide. Through rigorous research and innovative clinical trials conducted across these diverse locations over several years or even recently emerged expertise every small achievement brings us closer towards discovering breakthroughs that could ultimately transform lives affected by this complex disease
Which are the best cities for plaque psoriasis clinical trials?
When it comes to plaque psoriasis clinical trials, several cities have emerged as leading hubs for research. Miami, Florida takes the lead with 21 active trials investigating treatments like BMS-986165, Tildrakizumab, and Brodalumab. Following closely behind is New york City with 16 ongoing studies exploring options such as Nivolumab, risankizumab, and Rimegepant. Houston, Texas also shows promise in this field with 15 active trials focusing on risankizumab and other treatments like Guselkumab and Deucravacitinib. These three cities offer individuals suffering from plaque psoriasis an array of cutting-edge clinical trials that may pave the way for improved management of this chronic skin condition.
Which are the top treatments for plaque psoriasis being explored in clinical trials?
Plaque psoriasis research is rapidly advancing, with several promising treatments being explored in clinical trials. At the forefront is deucravacitinib, currently involved in three active trials and a total of six all-time plaque psoriasis trials since its introduction in 2021. Close behind is risankizumab, making strides with two ongoing trials and eleven all-time plaque psoriasis studies since 2016. Another noteworthy contender is ustekinumab, showing potential through two active trials and an impressive history of twenty-nine all-time plaque psoriasis clinical trials dating back to 2003. Lastly, guselkumab also joins the race with two current investigations and twenty-two previous plaque psoriasis studies since its first listing in 2013. These innovative therapies bring renewed hope for those living with plaque psoriasis as researchers continue their efforts towards finding effective solutions.
What are the most recent clinical trials for plaque psoriasis?
Exciting progress is being made in the field of plaque psoriasis treatment, with recent clinical trials offering promising insights. One such trial focuses on guselkumab, a potential therapy for plaque psoriasis that has shown positive results in Phase 3 studies. Additionally, DC-806 Dose A and BMS-986322 Dose 1 have demonstrated potential as effective treatments based on their respective Phase 2 trials. Another study examined the use of VTAMA cream (tapinarof) at a concentration of 1% to treat plaque psoriasis in a real-world setting. These ongoing trials provide hope for individuals living with this challenging skin condition by identifying new options and refining existing therapies.
What plaque psoriasis clinical trials were recently completed?
Several recent clinical trials have made significant progress in the field of plaque psoriasis research, paving the way for improved treatments. In June 2022, Janssen Research & Development completed a trial investigating the potential of JNJ-77242113 therapy. Similarly, AnaptysBio successfully wrapped up their trial on Imsidolimab low dose in April 2022. Meiji Pharma USA Inc.'s study on ME3183 concluded in March 2022, while UNION therapeutics' investigation into Orismilast modified release tablets reached completion in December 2021. These advancements exemplify the commitment and dedication researchers have towards finding more effective solutions for patients struggling with plaque psoriasis.